Jefferies lowers Scotts Miracle-Gro stock price target to $79 By Investing.com

Jefferies trimmed its price target on Scotts Miracle-Gro (SMG) to $79 from $82 but kept a Buy rating, implying about 24% upside from the current $63.68 share price. The company also reported Q2 2026 EPS of $4.53 versus $3.86 expected and revenue of $1.46 billion versus $1.41 billion expected, a beat of 17.36% on EPS and 3.55% on revenue. Management and Jefferies cited improving operations, cost reductions, and a path toward mid-single-digit growth, alongside a 22-year dividend track record.

Analysis

SMG is transitioning from a balance-sheet repair story to a cash-flow normalization story, which matters more than the headline target cut. The real driver is not the modest valuation adjustment, but the combination of better visibility on operations, easing leverage, and a resumption of credible growth math; that tends to rerate depressed consumer staples/ag inputs names faster than the market expects once earnings consistency improves.

The second-order winner is likely the equity itself relative to levered peers and adjacent discretionary/home-garden channels. If management can sustain mid-single-digit top-line growth while trimming debt, the equity story shifts from yield support to multiple expansion, and the current dividend becomes a floor rather than the primary thesis. That said, the market will likely demand proof over the next 1-2 quarters because this name has historically been punished for any inventory or margin wobble.

Near term, the biggest risk is that analysts extrapolate a clean recovery before consumer demand and channel inventory are fully normalized. A single weak spring/summer sell-through print would quickly compress the premium multiple case, especially if financing costs remain elevated and leverage progress stalls. The setup is therefore asymmetric over 3-6 months: good execution can re-rate the stock meaningfully, but any miss likely hits both the multiple and the dividend-support narrative.

Consensus may be underestimating how much of the upside is already tied to deleveraging rather than growth acceleration. If the market believes the company can simply defend margins and reduce debt, the stock can work even without dramatic demand upside; conversely, if growth is slower but cash conversion is strong, the downside may be limited. The better trade framing is to own the optionality on a continued operational reset, not to chase a full-growth re-rating immediately.

Key Decisions for Investors

• Go long SMG into the next 1-2 earnings windows, but size as a balance-sheet normalization trade rather than a pure growth call; the risk/reward improves if the stock re-tests the low-$60s after broad market weakness.
• Sell out-of-the-money covered calls against a long SMG position over the next 1-2 months to monetize elevated uncertainty; this fits a stock that can grind higher but is vulnerable to a disappointment-driven giveback.
• Pair trade: long SMG / short a higher-leverage consumer discretionary or home-improvement exposure over 3-6 months to isolate the deleveraging rerating if execution stays intact.
• If SMG breaks and holds above the low-$70s on volume after the next print, add via call spreads for a 2-3 quarter horizon; that would signal the market is finally paying for multiple expansion, not just yield.
• Reduce or hedge if the next channel commentary suggests any inventory bulge; that is the cleanest catalyst for the thesis to fail and would likely compress both earnings estimates and the premium multiple quickly.